Table 2.
Clinicopathological features of all patients with OSCC in three independent cohorts.
| Screening cohort | Training cohort | Testing cohort | P-value* | ||||
|---|---|---|---|---|---|---|---|
| (n=25) | (n=40) | (n=105) | |||||
| Age (years) | |||||||
| Mean ± SD | 63.28±10.20 | 63.10±9.63 | 60.96±12.74 | 0.492 † | |||
| Gender | |||||||
| Male | 13 (52.0%) | 22 (55.0%) | 64 (61.0%) | 0.641 | |||
| Female | 12 (48.0%) | 18 (45.0%) | 41 (39.0%) | ||||
| Smoking | |||||||
| Positive | 6 (24.0%) | 16 (40.0%) | 46 (43.8%) | 0.192 | |||
| Negative | 19 (76.0%) | 24 (60.0%) | 59 (56.2%) | ||||
| Drinking | |||||||
| Positive | 6 (24.0%) | 14 (35.0%) | 47 (44.8%) | 0.131 | |||
| Negative | 19 (76.0%) | 26 (65.0%) | 58 (55.2%) | ||||
| Pathological grade | |||||||
| pG1/pG2 | 17 (68.0%) | 26 (65.0%) | 61 (58.1%) | 0.561 | |||
| pG3 | 8 (32.0%) | 14 (35.0%) | 44 (41.9%) | ||||
| TNM stage | |||||||
| I | 5 (20.0%) | 4 (10.0%) | 16 (15.2%) | 0.919 | |||
| II | 6 (24.0%) | 10 (25.0%) | 30 (28.6%) | ||||
| III | 9 (36.0%) | 16 (40.0%) | 34 (32.4%) | ||||
| IV | 5 (20.0%) | 10 (25.0%) | 25 (23.8%) | ||||
| T stage | |||||||
| T1 | 7 (28.0%) | 11 (27.5%) | 22 (21.0%) | 0.796 | |||
| T2 | 8 (32.0%) | 16 (40.0%) | 39 (37.1%) | ||||
| T3 | 6 (24.0%) | 8 (20.0%) | 33 (31.4%) | ||||
| T4 | 4 (16.0%) | 5 (12.5%) | 11 (10.5%) | ||||
| N stage | |||||||
| N0 | 14 (56.0%) | 20 (50.0%) | 64 (61.0%) | 0.277 | |||
| N1 | 9 (36.0%) | 14 (35.0%) | 22 (21.0%) | ||||
| N2 | 2 (8.0%) | 6 (15.0%) | 19 (18.1%) | ||||
| Depth of invasion | |||||||
| DOI ≤ 5 mm | 7 (28.0%) | 20 (50.0%) | 56 (53.3%) | 0.157 | |||
| DOI > 5 and ≤10 mm | 10 (40.0%) | 13 (32.5%) | 34 (32.4%) | ||||
| DOI > 10 mm | 8 (32.0%) | 7 (17.5%) | 15 (14.3%) | ||||
| Extranodal extension | |||||||
| Positive | 7 (28.0%) | 11 (27.5%) | 27 (25.7%) | 0.960 | |||
| Negative | 18 (72.0%) | 29 (72.5%) | 78 (74.3%) | ||||
| Perineural invasion | |||||||
| Positive | 6 (24.0%) | 11 (27.5%) | 24 (22.9%) | 0.843 | |||
| Negative | 19 (76.0%) | 29 (72.5%) | 81 (77.1%) | ||||
| Vascular invasion | |||||||
| Positive | 6 (24.0%) | 9 (22.5%) | 23 (21.9%) | 0.974 | |||
| Negative | 19 (76.0%) | 31 (77.5%) | 82 (78.1%) | ||||
| Post-operative adjuvant treatment | |||||||
| Chemoradiotherapy | 13 (52.0%) | 22 (55.0%) | 45 (42.9%) | 0.368 | |||
| Negative | 12 (48.0%) | 18 (45.0%) | 60 (57.1%) | ||||
| Disease-free survival | |||||||
| Alive | 14 (56.0%) | 21 (52.5%) | 60 (57.1%) | 0.881 | |||
| Relapse or death | 11 (44.0%) | 19 (47.5%) | 45 (42.9%) | ||||
| Overall survival | |||||||
| Alive | 16 (64.0%) | 24 (60.0%) | 63 (60.0%) | 0.931 | |||
| Death | 9 (36.0%) | 16 (40.0%) | 42 (40.0%) | ||||
Mean ± standard deviation (SD) or n (%) were presented. † One Way ANOVA. * Chi-squared test. DOI: Depth of invasion; OSCC: oral squamous cell carcinoma.